Molecular Human Reproduction, Vol. 6, No. 1, 55-59,
January 2000
© 2000 European Society of Human Reproduction and Embryology
Uterus and pregnancy |
Tissue differences but limited sex steroid responsiveness of c-fos and c-jun in human fibroids and myometrium
1 Department of Obstetrics and Gynecology, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge and 2 Department of Women's and Children's Health, Section of Obstetrics and Gynecology, Uppsala University Hospital, Uppsala, Sweden
Abstract
Sex steroids influence the growth of mammalian uterine tissues and the proto-oncogenes c-fos and c-jun have been implicated in the cascade of cellular events induced by the cyclic influence of oestrogen and progesterone. To investigate the role of these proto-oncogenes for fibroid growth their mRNA expression was measured in myometrium and fibroids under different hormonal conditions, using a solution hybridization method. Fibroids and myometrium were collected at surgery from premenopausal, postmenopausal and pregnant women as well as women treated with a gonadotrophin releasing hormone agonist (GnRHa; Goserelin). The phase of the menstrual cycle was determined in all the untreated, premenopausal, non-pregnant women. The mRNA expression of c-fos and c-jun in fibroids was significantly lower than in homologous myometrium. No significant differences in c-fos expression were observed in myometrium, or fibroids, due to menstrual cycle phase, GnRHa treatment, pregnancy or the menopause. The c-jun expression in myometrium from pregnant women without fibroid disease was significantly higher than the corresponding control myometrium from premenopausal, non-pregnant women. These results demonstrate a tissue difference in the expression of c-fos and c-jun between myometrium and fibroids.
fibroids/hormones/human/proto-oncogenes
Notes
3 To whom correspondence should be addressed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Ball, J. W. Wang, S. Wong, B. Zielnik, J. Mitchell, N. Wang, M. B. Stemerman, and B. F. Mitchell Phorbol ester treatment of human myometrial cells suppresses expression of oxytocin receptor through a mechanism that does not involve activator protein-1 Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E922 - E928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Luo, L. Ding, J. Xu, R. S. Williams, and N. Chegini Leiomyoma and Myometrial Gene Expression Profiles and Their Responses to Gonadotropin-Releasing Hormone Analog Therapy Endocrinology, March 1, 2005; 146(3): 1074 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ding, J. Xu, X. Luo, and N. Chegini Gonadotropin Releasing Hormone and Transforming Growth Factor {beta} Activate Mitogen-Activated Protein Kinase/Extracellularly Regulated Kinase and Differentially Regulate Fibronectin, Type I Collagen, and Plasminogen Activator Inhibitor-1 Expression in Leiomyoma and Myometrial Smooth Muscle Cells J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5549 - 5557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chegini, J. Verala, X. Luo, J. Xu, and R. S. Williams Gene Expression Profile of Leiomyoma and Myometrium and the Effect of Gonadotropin Releasing Hormone Analogue Therapy Reproductive Sciences, April 1, 2003; 10(3): 161 - 171. [Abstract] [PDF]
|
|
|
|
|
|
N. Chegini and L. Kornberg Gonadotropin Releasing Hormone Analogue Therapy Alters Signal Transduction Pathways Involving Mitogen-Activated Protein and Focal Adhesion Kinases in Leiomyoma Reproductive Sciences, January 1, 2003; 10(1): 21 - 26. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Condon, S. Yin, B. Mayhew, R. A. Word, W.E. Wright, J.W. Shay, and W. E. Rainey Telomerase Immortalization of Human Myometrial Cells Biol Reprod, August 1, 2002; 67(2): 506 - 514. [Abstract] [Full Text] [PDF]
|
|